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Abstract 
Review on IRF4, with data on DNA/RNA, on the 
protein encoded and where the gene is implicated. 
Identity 
Other names: IRF-4, LSIRF, MUM1, NF-EM5 
HGNC (Hugo): IRF4 
Location: 6p25.3 
Local order: IRF4 is located on chromosome 6 at 
the telomeric extremity of the short arm, and lies 
between the DUSP22 (dual specificity phosphatase 
22) and EXOC2 (exocyst complex component 2) 
genes. 
Note 
IRF4 belongs to the IRF (interferon regulatory 
factors) family of transcription factors and is a 
critical transcriptional regulator of immune system 
development and function. 
DNA/RNA 
Description 
Gene of 19,4 kb with 9 exons and 8 introns. 
Exon 1, the 5' part of exon 2 and the 3' part of exon 
9 are non coding. 
Transcription 
Length of the transcript is 5314 bp. 
Coding sequence: CDS 114-1469. 
mRNA is expressed at high levels in lymphoid 
tissues, in skin and in tonsils. 
Protein 
Description 
Protein length: 451 amino acids.  
Calculated molecular weight of 51,8 kDa. 
Expression 
IRF4 protein is expressed predominantly in blood 
cells. However, its expression can also be detected 
in adipocytes and melanocytes. 
In blood cells, expression of IRF4 can be detected 
in T, B, DC and macrophages. Expression of IRF4 
in T and B cells is strongly induced by antigen 
receptor signaling. 
Localisation 
Nucleus. 
Function 
In the immune system, IRF4 is critical for 
development and maturation of multiple lineages of 
blood cells. In T cells development, IRF4 is 
essential for the differentiation of Th1, Th2, Th9, 
Th17 and T reg subsets. In B lymphocytes, IRF4 
promotes light chain rearrangement and 
transcription and is critical for B cell development 
at the pre-B stage. 
IRF4 antagonizes Notch signaling and limits the 
size of marginal zone B cells (Simonetti et al., 
2013). 
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In addition, IRF4 is essential for class-switching 
and plasma cell differentiation. In B cells, IRF4 
interacts with Ets family of trancription factor 
(PU.1/spi-B) through EICE site whereas in T cells, 
IRF4 interacts with AP-1 family of trancription 
factor (BATF) through AICE site. Also, IRF4 is 
required for the differentiation of dendritic cells 
(DCs), particularly the CD11b(+) subset (Schlitzer 
et al., 2013). In macrophages, IRF4 promotes the 
differentiation and polarisation to the M2 subtype 
also known as the tumor associated macrophages.  
Recent studies have identified a role of IRF4 in 
adipocyte biology. IRF4 has been shown to regulate 
enzymes required for lipolysis in adipocytes. 
Therefore, an adipocyte specific deletion of IRF4 
causes enhanced lipid synthesis, dysregulated lipid 
homeostasis eventually leading to obesity. 
Interestingly, in melanocytes IRF4 was recently 
identified to cooperate with another transcription 
factor, MITF to positively regulate the expression 
of tyrosinase gene required for melanin synthesis. 
Additionally, the SNPs in the IRF4 gene locus have 
been identified as risk alleles for developing 
melanoma. 
Homology 
Among IRF family members, IRF4 is highly 
homologous to IRF8. 
Mutations 
Germinal 
SNPs in the IRF4 gene locus have been identified 
in patients with chronic lymphocytic leukemia and 
melanoma. 
Somatic 
Somatic mutations in DNA binding domain of IRF4 
have been identified in a small subset (1,5%) of 
chronic lymphocytic leukemia (CLL) patients. 
Implicated in 
Multiple myeloma (MM) 
Disease 
Multiple myeloma (MM) is a plasma cell derived 
malignancy with a particularly aggressive clinical 
course. IRF4 is obligatory required for the terminal 
differetiation of mature B cells to plasma cells and 
has been shown to play a central role in the 
pathogenesis of MM. IRF4 is recurrently 
translocated and juxtaposed to the IgH promoter 
t(6;14)(p25;q32) in a significant proportion (~21%) 
of MM cases. More commonly, IRF4 have been 
shown to be overexpressed without genetic 
alterations in majority of MM cases and MM cells 
are particularly sensitive to the down-regulation of 
IRF4. 
Cytogenetics 
t(6;14)(p25;q32) --> IRF4 - IgH. 
Hybrid/Mutated gene 
The translocation juxtaposes the IgH locus to the 
IRF4 gene. 
Oncogenesis 
The precise mechanism for pathogenesis of MM in 
presence of high levels of IRF4 is mediated by an 
autoregulatory loop established between IRF4 and 
c-myc in MM cells. Recently, IRF4 has been shown 
to regulate caspase-10 leading to disruption of 
normal autophagy mechanisms in MM cells 
thereby, causing prolonged survival of these cells. 
Chronic lymphocytic leukemia (CLL) 
Disease 
CLL is the most common adult leukemia in the 
western countries. It is a heterogeneous B-cell 
malignancy marked by progressive accumulation of 
CD5 positive mature B lymphocytes. A Genome 
Wide Association Study (GWAS) recently 
identified SNPs in the 3' UTR of IRF4 gene locus in 
patients with CLL. The individuals carrying the risk 
alleles harboring the SNPs have lower levels of 
IRF4 and poorer outcomes compared to individuals 
carrying the non-risk allele. Another study 
identified mutations in the DNA binding domain of 
IRF4 in a small subset (1,5%) of CLL cases. More 
recently, using two distinct murine genetic models, 
it has been shown that low levels of IRF4 are 
causally related to the development of CLL. 
Prognosis 
CLL patients with low levels of IRF4 have 
aggressive disease course and poor prognosis. 
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Cytogenetics 
Although reciprocal translocations are extremely 
rare in CLL, a translocation disrupting IRF4 gene 
locus t(1;6)(p35.3;p25.2) was identified in a small 
subset of CLL patients with aggressive disease. 
Hybrid/Mutated gene 
Mutations in the DNA binding domain of IRF4 
with a yet undefined function in B cells were 
identified in a small subset of CLL cases. 
Oncogenesis 
The precise mechanism for oncogenesis of CLL in 
presence of low levels of IRF4 is not yet known. 
Diffused large B cell lymphoma 
(DLBCL) 
Disease 
Diffuse large B cell lymphoma represents a 
heterogeneous malignancy that arises 
spontaneously or develop from pre-existing 
leukemia. On the basis of gene expression profiling 
DLBCL is divided into three distinct subtypes 
namely the germinal center subtype (GCB), the 
activated B cell subtype (ABC) and the mediastinal 
subtype. The three subtypes presumably arise from 
three distinct B cell subtypes. IRF4 is primarily 
overexpressed in the ABC type of DLBCL while 
GCB subtype is marked by lower expression of 
IRF4. 
Prognosis 
IRF4 is overexpressed in the ABC type DLBCL 
which is most aggressive form of DLBCL and have 
poorer patient outcomes compared to other 
subtypes. 
Cytogenetics 
IRF4 is overexpressed in a small group of patients 
with a reciprocal translocation between IgG locus 
and the IRF4 t(1;6)(p35.3;p25.2). The patients 
carrying the translocation primarily belong to GCB 
or follicular lymphoma grade 3 type is associated 
with favorable patient outcomes. 
Oncogenesis 
IRF4 induces the expression of transcription factor 
Blimp-1 and directly suppresses the expression of 
Bcl-6 to allow terminal differentiation of activated 
B cells to plasma cells. However, this molecular 
network is short circuited in ABC DLBCL by 
recurrent mutational inactivation of Blimp-1. 
Additionally, mutations located in the promoter 
region of Bcl-6 that disrupt the IRF4 binding sites 
and leads to enhanced expression of Bcl-6 were 
identified in a small group of patients. These 
genetic events disrupt the molecular network 
required for plasma cell differentiation. However, 
the precise functional role of IRF4 in pathogenesis 
of ABC type DLBCL is not well defined. 
Hodgkins lymphoma (HL) 
Disease 
Hodgkins lymphoma (HL) is an enigmatic B cell 
malignancy that is characterized by lack of 
expression of several B cell markers.  
The Hodgkin and Reed Sternberg (HRS) cells 
present in HL cases are presumably derived from 
germinal center B cells. IRF4 is overexpressed in 
majority of classical HL cases and is shown to 
mediate the survival of these cells. Paradoxically, 
the SNPs in IRF4 linked to its lower expression 
levels and associated with the development of CLL 
are also shown to be linked to the risk of 
developing HL. 
Oncogenesis 
Whether the overexpression of IRF4 in HRS cells 
of HL is causal is unclear. However, some studies 
have linked the survival and proliferation of HRS 
cells to the expression of IRF4. 
Primary cutaneous anaplastic large 
cell lymphoma (C-ALCL) 
Disease 
Primary cutaneous anaplastic large cell lymphoma 
(C-ALCL) is a T cell lymphoma with an indolent 
disease course and presence of tumor lesions in the 
skin. The lesions in C-ALCL almost never spread 
extra-cutaneously and often regress spontaneously. 
IRF4 is overexpressed in C-ALCL but not in the 
more aggressive form of the disease known as 
peripheral T cell lymphoma not otherwise specified 
(PTCL-NOS). The overexpression of IRF4 in some 
cases is associated with a recurrent translocations a 
subset of them placing the IRF4 gene next to the T 
cell receptor alpha (TCRA) promoter 
t(6;14)(p25;q11.2). Other translocations identified 
do not involve TCRA. 
Cytogenetics 
IRF4 is translocated primarily in the C-ALCL 
however the precise breakpoints are not defined. In 
a small subset of the cases with translocations IRF4 
is juxtaposed to the TCRA locus 
t(6;14)(p25;q11.2). 
B cell acute lymphoblastic leukemia 
(B-ALL) 
Disease 
B cell acute lymphoblastic leukemia (B-ALL) is a 
B cell malignancy derived from early B cells. IRF4 
is shown to play a tumor suppressive role in B-
ALL. IRF4 is shown to suppress the oncogenesis of 
both BCR-ABL and c-myc induced B-ALL. 
Oncogenesis 
IRF4 inhibits B-ALL by regulating the expression 
of negative regulators of cell cycle p27. 
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Chronic myeloid leukemia (CML) 
Disease 
Chronic myeloid leukemia (CML) is a 
myeloproliferative disorder marked by clonal 
expansion of granulocytes. It is associated with a 
hallmark translocation and presence of a fusion 
BCR-ABL protein in majority of patients. IRF4 is 
shown to be underexpressed in CML patients along 
with its highly homologous family member IRF8. 
However the functional role of IRF4 in CML is not 
well characterized. 
Virus implicated malignancies 
Disease 
Viruses like Epstein Barr virus (EBV), human T 
cell leukemia virus-1 (HTLV1) and Kaposi 
Sarcoma associated herpes virus (KSHV/HHV-8) 
are implicated in B cell malignancies, adult T cell 
leukemia (ATL) and primary effusion lymphoma 
(PEL) respectively. The proteins encoded by these 
viruses, directly or indirectly activate NF-kB 
signaling which in turn activates the expression of 
IRF4. As a result IRF4 is overexpressed in these 
virus implicated malignancies. The knockdown of 
IRF4 in EBV transformed B cells lead to down-
regulation of genes involved in cellular 
proliferation. The role of IRF4 in HTLV-1 induced 
ATL is not clear however few reports indicate its 
involvement in regulation of cell cycle associated 
genes. The role of IRF4 in KSHV induced kaposi's 
sarcoma and PEL is ambiguous. KSHV encodes 
viral homologs of cellular IRFs called vIRFs. The 
vIRF4 is shown to inhibit the function of cellular 
IRF4 leading to induction of lytic cycle for KSHV 
replication. 
Oncogenesis 
The role of IRF4 in these viral implicated 
malignancies is still unclear. However, the 
activation status of NF-kB by these viruses 
invariably co-relates with IRF4 expression in these 
cells. 
Skin cancer 
Disease 
Skin cancer is associated with malignant or non-
malignant lesions on the skin. Based on the cell of 
origin, skin cancer can be divided into three types: 
basal cell carcinoma, squamous cell carcinoma and 
melanoma. The differential skin pigmentation 
induced by melanin production alters the risk for 
skin cancer. Particularly individuals with light skin 
tones and hence low melanin secretion are more 
predisposed to developing skin cancer. Until 
recently there were no known reports for a role of 
IRF4 in melanocytes. However recently, SNPs 
identified in the IRF4 gene locus have been shown 
to be associated with skin pigmentation and the risk 
for developing skin cancer. The SNP identified in 
the screen map to a putative enhancer region in the 
IRF4 gene locus. 
Oncogenesis 
Recently, the SNP identified in IRF4 locus were 
demonstrated to decrease IRF4 expression by 
disruption of specific transcription factor binding 
sites. Additionally, IRF4 corroborates with 
micropthalmia associated transcription factor 
(MITF) to regulate the expression of enzyme 
tyrosinase responsible for melanin production. 
These studies point towards a critical role for IRF4 
in melanocyte biology and also its association with 
skin cancer. 
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